Cancer in Kidney Transplant Recipients

Cancer poses a significant challenge in kidney transplant recipients primarily due to the immunosuppressive medications required to prevent organ rejection, which unfortunately increase the risk of malignancies. This relationship has dramatic implications, as malignancies contribute to approximately 20% of mortalities in this group. Traditional oncology treatments are less effective in these immunocompromised patients compared to non-immunosuppressed individuals, reflecting a complex interplay of immunity, drug interactions, and disease management challenges. The advent of immune checkpoint inhibitors (ICI) has dramatically improved outcomes in oncology, yet their application in organ transplant recipients is limited due to high risks of rejection and adverse allo-immune responses.

This Research Topic aims to examine the intricate dynamics of diagnosing and managing cancer in kidney transplant recipients. It seeks to explore existing barriers in effective cancer treatment, underscore the necessity for enhanced cancer screening protocols to allow for early detection, and discuss the nuanced balance required in managing immunosuppression during oncologic treatment. By highlighting these challenges and opportunities, the research intends to amalgamate insights from both clinical practices and ongoing research, fostering a better understanding that could translate into improved patient care.

To gather further insights into the specific challenges and advancements within this sphere, we welcome articles addressing, but not limited to, the following themes:

- Utilization of immune checkpoint inhibitors in kidney transplant recipients
- Management of immunosuppression following a cancer diagnosis
- Advancements in oncology protocols tailored for kidney transplant recipients
- Comprehensive assessment of cancer risk among kidney transplant recipients
- Future perspectives and innovations in cancer treatments for this unique population

These contributions will help enhance our understanding and effectiveness in managing both transplantation and oncology care, ultimately improving survival rates and quality of life for kidney transplant recipients facing cancer.

Keywords: Immune Checkpoint Inhibitors, Transplant Rejection, Oncology, Cancer Risk

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.